Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

Ana Lleo, Andrea Aglitti, Alessio Aghemo, Patrick Maisonneuve, Savino Bruno, Marcello Persico, Maria Rendina, Alessia Ciancio, Pietro Lampertico, Maurizia R. Brunetto, Vito Di Marco, Massimo Zuin, Pietro Andreone, Erica Villa, Giulia Troshina, Elisabetta Degasperi, Barbara Coco, Vincenza Calvaruso, Alessia M. Giorgini, Fabio ContiAlfredo Di Leo, Luca Marzi, Vincenzo Boccaccio, Simona Bollani, Massimo Colombo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs), the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAA-treated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous HCC. Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per 100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alpha-fetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previous HCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was the strongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portal hypertension have a lower incidence rate of HCC (1.0 per 100-year). Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP and signs of portal hypertension can help to stratify the risk of HCC.

Original languageEnglish
Pages (from-to)310-317
JournalDigestive and Liver Disease
Volume51
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint

Antiviral Agents
Hepatocellular Carcinoma
Recurrence
alpha-Fetoproteins
Portal Hypertension
Christianity
Incidence
Italy
Liver

Keywords

  • Cirrhosis
  • Direct antiviral agents
  • HCV
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. / Lleo, Ana; Aglitti, Andrea; Aghemo, Alessio; Maisonneuve, Patrick; Bruno, Savino; Persico, Marcello; Rendina, Maria; Ciancio, Alessia; Lampertico, Pietro; Brunetto, Maurizia R.; Di Marco, Vito; Zuin, Massimo; Andreone, Pietro; Villa, Erica; Troshina, Giulia; Degasperi, Elisabetta; Coco, Barbara; Calvaruso, Vincenza; Giorgini, Alessia M.; Conti, Fabio; Di Leo, Alfredo; Marzi, Luca; Boccaccio, Vincenzo; Bollani, Simona; Colombo, Massimo.

In: Digestive and Liver Disease, Vol. 51, No. 2, 2019, p. 310-317.

Research output: Contribution to journalArticle

Lleo, A, Aglitti, A, Aghemo, A, Maisonneuve, P, Bruno, S, Persico, M, Rendina, M, Ciancio, A, Lampertico, P, Brunetto, MR, Di Marco, V, Zuin, M, Andreone, P, Villa, E, Troshina, G, Degasperi, E, Coco, B, Calvaruso, V, Giorgini, AM, Conti, F, Di Leo, A, Marzi, L, Boccaccio, V, Bollani, S & Colombo, M 2019, 'Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals', Digestive and Liver Disease, vol. 51, no. 2, pp. 310-317. https://doi.org/10.1016/j.dld.2018.10.014
Lleo, Ana ; Aglitti, Andrea ; Aghemo, Alessio ; Maisonneuve, Patrick ; Bruno, Savino ; Persico, Marcello ; Rendina, Maria ; Ciancio, Alessia ; Lampertico, Pietro ; Brunetto, Maurizia R. ; Di Marco, Vito ; Zuin, Massimo ; Andreone, Pietro ; Villa, Erica ; Troshina, Giulia ; Degasperi, Elisabetta ; Coco, Barbara ; Calvaruso, Vincenza ; Giorgini, Alessia M. ; Conti, Fabio ; Di Leo, Alfredo ; Marzi, Luca ; Boccaccio, Vincenzo ; Bollani, Simona ; Colombo, Massimo. / Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. In: Digestive and Liver Disease. 2019 ; Vol. 51, No. 2. pp. 310-317.
@article{f57cabe4426a46d9896256b8ea8f1f1b,
title = "Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals",
abstract = "Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs), the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAA-treated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous HCC. Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per 100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alpha-fetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previous HCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was the strongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portal hypertension have a lower incidence rate of HCC (1.0 per 100-year). Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP and signs of portal hypertension can help to stratify the risk of HCC.",
keywords = "Cirrhosis, Direct antiviral agents, HCV, Hepatocellular carcinoma",
author = "Ana Lleo and Andrea Aglitti and Alessio Aghemo and Patrick Maisonneuve and Savino Bruno and Marcello Persico and Maria Rendina and Alessia Ciancio and Pietro Lampertico and Brunetto, {Maurizia R.} and {Di Marco}, Vito and Massimo Zuin and Pietro Andreone and Erica Villa and Giulia Troshina and Elisabetta Degasperi and Barbara Coco and Vincenza Calvaruso and Giorgini, {Alessia M.} and Fabio Conti and {Di Leo}, Alfredo and Luca Marzi and Vincenzo Boccaccio and Simona Bollani and Massimo Colombo",
year = "2019",
doi = "10.1016/j.dld.2018.10.014",
language = "English",
volume = "51",
pages = "310--317",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

AU - Lleo, Ana

AU - Aglitti, Andrea

AU - Aghemo, Alessio

AU - Maisonneuve, Patrick

AU - Bruno, Savino

AU - Persico, Marcello

AU - Rendina, Maria

AU - Ciancio, Alessia

AU - Lampertico, Pietro

AU - Brunetto, Maurizia R.

AU - Di Marco, Vito

AU - Zuin, Massimo

AU - Andreone, Pietro

AU - Villa, Erica

AU - Troshina, Giulia

AU - Degasperi, Elisabetta

AU - Coco, Barbara

AU - Calvaruso, Vincenza

AU - Giorgini, Alessia M.

AU - Conti, Fabio

AU - Di Leo, Alfredo

AU - Marzi, Luca

AU - Boccaccio, Vincenzo

AU - Bollani, Simona

AU - Colombo, Massimo

PY - 2019

Y1 - 2019

N2 - Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs), the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAA-treated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous HCC. Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per 100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alpha-fetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previous HCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was the strongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portal hypertension have a lower incidence rate of HCC (1.0 per 100-year). Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP and signs of portal hypertension can help to stratify the risk of HCC.

AB - Background: Despite the dramatic improvement in viral eradication rates that has been reached with direct antiviral agents (DAAs), the real benefit of viral eradication after DAAs on hepatocellular carcinoma (HCC) development is still controversial. Aim: To prospectively assess the risk of HCC occurrence and early recurrence in a large cohort of DAA-treated HCV-cirrhotic patients and to identify potential predictors of HCC development. Methods: We analyzed data prospectively collected from 1927 consecutive HCV-infected cirrhotic patients treated with DAA from January to December 2015 in 10 tertiary liver centers in Italy and followed-up for one year after therapy. 161 patients had a previous HCC. Results: 38/161 subjects developed tumor recurrence during the follow-up (recurrence rate = 24.8 per 100-year), patients with SVR had a significantly lower rate of recurrence. Lack of SVR and alpha-fetoprotein (AFP) were independent predictors of HCC recurrence. 50/1766 patients without a previous HCC history developed HCC during follow-up (incidence rate = 2.4 per 100-year). Lack of SVR was the strongest predictor of HCC development. Furthermore, patients with SVR and no stigmata of portal hypertension have a lower incidence rate of HCC (1.0 per 100-year). Conclusions: SVR is associated with a significant decrease of recurrent or de novo HCC. Baseline AFP and signs of portal hypertension can help to stratify the risk of HCC.

KW - Cirrhosis

KW - Direct antiviral agents

KW - HCV

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85057004705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057004705&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2018.10.014

DO - 10.1016/j.dld.2018.10.014

M3 - Article

AN - SCOPUS:85057004705

VL - 51

SP - 310

EP - 317

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 2

ER -